| Analysis | Samples | Factors | Units |
|---|---|---|---|
| Reversed phase POSITIVE ION MODE | Control 01_1_7_1_935 | Treatment:Control | AU |
| Reversed phase POSITIVE ION MODE | Control 01_2_7_1_936 | Treatment:Control | AU |
| Reversed phase POSITIVE ION MODE | Control 02_1_8_1_937 | Treatment:Control | AU |
| Reversed phase POSITIVE ION MODE | Control 02_2_8_1_938 | Treatment:Control | AU |
| Reversed phase POSITIVE ION MODE | Control 03_1_9_1_939 | Treatment:Control | AU |
| Reversed phase POSITIVE ION MODE | Control 03_2_9_1_940 | Treatment:Control | AU |
| Reversed phase POSITIVE ION MODE | Control 04_1_10_1_941 | Treatment:Control | AU |
| Reversed phase POSITIVE ION MODE | Control 04_2_10_1_942 | Treatment:Control | AU |
| Reversed phase POSITIVE ION MODE | DF nP 01_1_15_1_951 | Treatment:Drug Free PLGA Nanoparticle | AU |
| Reversed phase POSITIVE ION MODE | DF nP 01_2_15_1_952 | Treatment:Drug Free PLGA Nanoparticle | AU |
| Reversed phase POSITIVE ION MODE | DF nP 02_1_16_1_953 | Treatment:Drug Free PLGA Nanoparticle | AU |
| Reversed phase POSITIVE ION MODE | DF nP 02_2_16_1_954 | Treatment:Drug Free PLGA Nanoparticle | AU |
| Reversed phase POSITIVE ION MODE | DF nP 03_1_17_1_955 | Treatment:Drug Free PLGA Nanoparticle | AU |
| Reversed phase POSITIVE ION MODE | DF nP 03_2_17_1_956 | Treatment:Drug Free PLGA Nanoparticle | AU |
| Reversed phase POSITIVE ION MODE | DF nP 04_1_18_1_957 | Treatment:Drug Free PLGA Nanoparticle | AU |
| Reversed phase POSITIVE ION MODE | DF nP 04_2_18_1_958 | Treatment:Drug Free PLGA Nanoparticle | AU |
| Reversed phase POSITIVE ION MODE | Free Drug 01_1_11_1_943 | Treatment:Free PTX | AU |
| Reversed phase POSITIVE ION MODE | Free Drug 01_2_11_1_944 | Treatment:Free PTX | AU |
| Reversed phase POSITIVE ION MODE | Free Drug 02_1_12_1_945 | Treatment:Free PTX | AU |
| Reversed phase POSITIVE ION MODE | Free Drug 02_2_12_1_946 | Treatment:Free PTX | AU |
| Reversed phase POSITIVE ION MODE | Free Drug 03_1_13_1_947 | Treatment:Free PTX | AU |
| Reversed phase POSITIVE ION MODE | Free Drug 03_2_13_1_948 | Treatment:Free PTX | AU |
| Reversed phase POSITIVE ION MODE | Free Drug 04_1_14_1_949 | Treatment:Free PTX | AU |
| Reversed phase POSITIVE ION MODE | Free Drug 04_2_14_1_950 | Treatment:Free PTX | AU |
| Reversed phase POSITIVE ION MODE | nP 01_1_19_1_959 | Treatment:PTX-PLGA Nanoparticle | AU |
| Reversed phase POSITIVE ION MODE | nP 01_2_19_1_960 | Treatment:PTX-PLGA Nanoparticle | AU |
| Reversed phase POSITIVE ION MODE | nP 02_1_20_1_961 | Treatment:PTX-PLGA Nanoparticle | AU |
| Reversed phase POSITIVE ION MODE | nP 02_2_20_1_962 | Treatment:PTX-PLGA Nanoparticle | AU |
| Reversed phase POSITIVE ION MODE | nP 03_1_21_1_963 | Treatment:PTX-PLGA Nanoparticle | AU |
| Reversed phase POSITIVE ION MODE | nP 03_2_21_1_964 | Treatment:PTX-PLGA Nanoparticle | AU |
| Reversed phase POSITIVE ION MODE | nP 04_1_22_1_965 | Treatment:PTX-PLGA Nanoparticle | AU |
| Reversed phase POSITIVE ION MODE | nP 04_2_22_1_966 | Treatment:PTX-PLGA Nanoparticle | AU |
Return to study ST002248 main page
Download data matrix(Quantitative multi-Omics analysis of paclitaxel-loaded Poly(lactide-co-glycolide) nanoparticles for identification of potential biomarkers for head and neck cancer Reversed phase POSITIVE ION MODE)
- Metabolomics Workbench
|